Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL726963 | 1.00 | KDM4E (0.45) | KDM4EALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL1092792 | 0.86 | MTNR1A (0.41) | HSD17B10TSHRHTR2AHPGD | |
| SCHEMBL1092757 | 0.86 | SLC6A4 (0.41) | CDK4CCND1 | |
| SCHEMBL1092753 | 0.86 | SLC6A4 (0.41) | CDK4CCND1 | |
| SCHEMBL1092795 | 0.86 | MTNR1A (0.41) | HSD17B10TSHRHTR2AHPGD | |
| SCHEMBL1093592 | 0.84 | SLC6A4 (0.41) | HTR2AHTR2CHTR2BKCNH2CDK4 | |
| SCHEMBL724656 | 0.84 | SLC6A4 (0.41) | KDM4EALDH1A1HSD17B10MAPTHTR2A | |
| SCHEMBL725718 | 0.84 | MPO (0.43) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL724657 | 0.84 | SLC6A4 (0.41) | KDM4EALDH1A1HSD17B10MAPTHTR2A | |
| SCHEMBL725141 | 0.84 | HTR2A (0.42) | HTR1AHTR2AHTR2CHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116394-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2006-06-01 | — | — | US | claimed |
| EP-1560584-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2005-10-12 | — | — | EP | claimed |
| EP-1560584-A2 | FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2005-08-10 | — | — | EP | claimed |
| US-20040147580-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-07-29 | — | — | US | claimed |
| WO-2003088897-A2 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-10-30 | — | — | WO | claimed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2579863-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | Affinium Pharmaceuticals, Inc. (CA) | 2013-04-17 | — | — | EP | disclosed |
| US-8153652-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| WO-2011156811-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-12-15 | — | — | WO | disclosed |
| US-20110098277-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-20060116394-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2006-06-01 | — | — | US | disclosed |
| US-7049310-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-05-23 | — | — | US | disclosed |
| EP-1608377-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | Affinium Pharmaceuticals, Inc. (CA) | 2005-12-28 | — | — | EP | disclosed |
| EP-1560584-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2005-10-12 | — | — | EP | disclosed |
| EP-1560584-A2 | FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004082586-A2 | PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040147580-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-07-29 | — | — | US | disclosed |
| WO-2003088897-A2 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | LPO, MPO, MMP8 | KDM4E 2691/4885ALDH1A1 745/4885KMT2A 3066/4885 |
| US-20060116394-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI2 | KDM4E 4668/4885ALDH1A1 4020/4885KMT2A 4356/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | KDM4E 4139/4885ALDH1A1 4188/4885KMT2A 4353/4885 |
| US-20040147580-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI1 | KDM4E 4602/4885ALDH1A1 3962/4885KMT2A 4261/4885 |
| US-20110098277-A1 | Fab I Inhibitors | SERPINB1, TMBIM6, GDI2 | KDM4E 4668/4885ALDH1A1 4020/4885KMT2A 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.